Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2000-06-22
2002-12-31
Caputa, Anthony C. (Department: 1642)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C536S023500, C536S024300, C536S024330, C435S325000, C435S070100, C435S320100, C435S004000, C435S006120
Reexamination Certificate
active
06500642
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to a mammalian cDNA which encodes a mammalian T cell death-associated gene and to the use of the cDNA and the encoded protein in the diagnosis and treatment of breast cancer.
BACKGROUND OF THE INVENTION
Phylogenetic relationships among organisms have been demonstrated many times, and studies from a diversity of prokaryotic and eukaryotic organisms suggest a more or less gradual evolution of molecules, biochemical and physiological mechanisms, and metabolic pathways. Despite different evolutionary pressures, the proteins of nematode, fly, rat, and man have common chemical and structural features and generally perform the same cellular function. Comparisons of the nucleic acid and protein sequences from organisms where structure and/or function are known accelerate the investigation of human sequences and allow the development of model systems for testing diagnostic and therapeutic agents for human conditions, diseases, and disorders.
Apoptosis is the genetically controlled process by which unneeded or defective cells undergo programmed cell death. Apoptotic events are part of the normal developmental programs of many multicellular organisms. Selective elimination of cells is as important for morphogenesis and tissue remodeling as is cell proliferation and differentiation. Lack of apoptosis may result in hyperplasia and other disorders associated with increased cell proliferation. Apoptosis is also a critical component of the immune response. Immune cells such as cytotoxic T-cells and natural killer cells prevent the spread of disease by inducing apoptosis in tumor cells and virus-infected cells. In addition, immune cells that fail to distinguish self molecules from foreign molecules must be eliminated by apoptosis to avoid an autoimmune response.
Apoptotic cells undergo distinct morphological changes. Hallmarks of apoptosis include cell shrinkage, nuclear and cytoplasmic condensation, and alterations in plasma membrane topology. Biochemically, apoptotic cells are characterized by increased intracellular calcium concentration, fragmentation of chromosomal DNA into nucleosomal-length units, and expression of novel cell surface components.
The molecular mechanisms of apoptosis are highly conserved, and many of the key protein regulators and effectors of apoptosis have been identified. Apoptosis generally proceeds in response to a signal which is transduced intracellularly and results in altered patterns of gene expression and protein activity. Signaling molecules such as hormones and cytokines are known to regulate apoptosis both positively and negatively through their interactions with cell surface receptors. Transcription factors also play an important role in the onset of apoptosis. A number of downstream effector molecules, especially proteases, have been implicated in the degradation of cellular components and the proteolytic activation of other apoptotic effectors.
The rat ventral prostate (RVP) is a model system for the study of hormone-regulated apoptosis. RVP epithelial cells undergo apoptosis in response to androgen deprivation. Messenger RNA (mRNA) transcripts that are up-regulated in the apoptotic RVP have been identified (Briehl and Miesfeld (1991) Mol Endocrinol 5:1381-1388). One such transcript encodes RVP.1, the precise role of which in apoptosis has not been determined. The human homolog, hRVP1, is 89% identical to the rat protein (Katahira et al. (1997) J Biol Chem 272:26652-26658). hRVP1 is 220 amino acids in length and contains four transmembrane domains. hRVP1 is highly expressed in the lung, intestine, and liver. Interestingly, hRVP1 functions as a low affinity receptor for the
Clostridium perfringens
enterotoxin, a causative agent of diarrhea in humans and other animals.
Apoptosis also plays a critical role in the developing immune system and in the down-regulation of the immune response. Immature T-cells in the thymus are subjected to negative selection, a process that eliminates self-reactive T-cells which would otherwise mount an autoimmune response. Negative selection occurs through apoptotic mechanisms triggered by activation of the T-cell receptor (TCR) on the T-cell surface. A similar mechanism exists for the elimination of mature, antigen-activated T-cells when down-regulation of the immune response is required. This activation-induced apoptosis is mediated by another cell surface receptor, Fas, which is a member of the tumor necrosis factor receptor family. Fas expression is up-regulated in a mouse T cell hybridoma cell line in response to TCR stimulation and requires the activity of yet another gene, T cell death-associated gene 51 (TDAG51; Park et al. (1996) Immunity 4:583-591). TDAG51 encodes a novel 261-amino acid protein, which may be a potential transcription factor. Expression of TDAG51 is dependent on protein kinase C activation and is required for induction of Fas expression (Wang et al. (1998) J Immunol 161:2201-2207). The discovery of a mammalian cDNA encoding a new molecule associated with apoptosis satisfies a need in the art by providing compositions which are useful in the diagnosis and treatment of breast cancer.
SUMMARY OF THE INVENTION
The invention is based on the discovery of a mammalian cDNA which encodes MAPOP-3 which is useful in the diagnosis and treatment of breast cancers, particularly adenocarcinoma.
The invention provides an isolated mammalian cDNA or a fragment thereof encoding a mammalian protein or a portion thereof selected from the group consisting of an amino acid sequence of SEQ ID NO:1, a variant having 45% identity to the amino acid sequence of SEQ ID NO:1, an antigenic epitope of SEQ ID NO:1, an oligopeptide of SEQ ID NO:1, and a biologically active portion of SEQ ID NO:1. The invention also provides an isolated mammalian cDNA or the complement thereof selected from the group consisting of a nucleic acid sequence of SEQ ID NO:2, a variant having at least 84% identity to the nucleic acid sequence of SEQ ID NO:2, a fragment of SEQ ID NOs:3-33, an oligonucleotide of SEQ ID NO:2. The invention additionally provides a composition, a substrate, and a probe comprising the cDNA, or the complement of the cDNA, encoding MAPOP-3. The invention further provides a vector containing the cDNA, a host cell containing the vector and a method for using the cDNA to make MAPOP-3. The invention still further provides a transgenic cell line or organism comprising the vector containing the cDNA encoding MAPOP-3. The invention additionally provides a mammalian fragment or the complement thereof selected from the group consisting of SEQ ID NOs:9-33. In one aspect, the invention provides a substrate containing at least one of these fragments. In a second aspect, the invention provides a probe comprising the fragment which can be used in methods of detection, screening, and purification. In a further aspect, the probe is a single stranded complementary RNA or DNA molecule.
The invention provides a method for using a cDNA to detect the differential expression of a nucleic acid in a sample comprising hybridizing a probe to the nucleic acids, thereby forming hybridization complexes and comparing hybridization complex formation with a standard, wherein the comparison indicates the differential expression of the cDNA in the sample. In one aspect, the method of detection further comprises amplifying the nucleic acids of the sample prior to hybridization. In another aspect, the method showing differential expression of the cDNA is used to diagnose breast cancer. In another aspect, the cDNA or a fragment or a complement thereof may comprise an element on an array.
The invention additionally provides a method for using a cDNA or a fragment or a complement thereof to screen a library or plurality of molecules or compounds to identify at least one ligand which specifically binds the cDNA, the method comprising combining the cDNA with the molecules or compounds under conditions allowing specific binding, and detecting specific binding to the cDNA, thereby identifying a ligand which specifically binds t
Corley Neil C.
Guegler Karl J.
Patterson Chandra
Yue Henry
Caputa Anthony C.
Holleran Anne L.
Incyte Genomics Inc.
Incyte Genomics, Inc.
LandOfFree
Molecule associated with apoptosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Molecule associated with apoptosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Molecule associated with apoptosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2920302